Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Neurophth to Begin Australian Trial of Gene Therapy for Visual Impairment

publication date: Sep 8, 2023

Neurophth Therapeutics, a Wuhan-San Diego ophthalmology biotech, was approved to start clinical trials in Australia of NFS-05, a gene therapy for Autosomal Dominant Optic Atrophy (ADOA). ADOA is an autosomal dominant inherited optic neuropathy that causes bilateral, slowly progressing visual impairment. Neurophth points out that the eye is a closed sphere with little effect on the rest of the body, making it a natural target for gene therapies. NFS-05 delivers the OPA1 gene, the cause of 80% of ADOA cases. In August, Neurophth closed a $95 million Series C+ financing. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital